Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 16, 2022

SELL
$23.34 - $36.08 $432,350 - $668,345
-18,524 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$17.63 - $37.1 $97,123 - $204,383
5,509 Added 42.33%
18,524 $634,000
Q3 2021

Nov 15, 2021

SELL
$12.95 - $49.69 $279,784 - $1.07 Million
-21,605 Reduced 62.41%
13,015 $231,000
Q2 2021

Aug 11, 2021

SELL
$25.57 - $44.88 $332,410 - $583,440
-13,000 Reduced 27.3%
34,620 $1.55 Million
Q1 2021

May 17, 2021

BUY
$19.02 - $31.15 $120,187 - $196,836
6,319 Added 15.3%
47,620 $1.23 Million
Q4 2020

Feb 16, 2021

SELL
$18.49 - $25.13 $1,830 - $2,487
-99 Reduced 0.24%
41,301 $833,000
Q3 2020

Nov 16, 2020

BUY
$15.19 - $22.4 $325,066 - $479,359
21,400 Added 107.0%
41,400 $809,000
Q2 2020

Aug 14, 2020

BUY
$6.19 - $18.84 $123,800 - $376,800
20,000 New
20,000 $353,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.99B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Susquehanna Fundamental Investments, LLC Portfolio

Follow Susquehanna Fundamental Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna Fundamental Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna Fundamental Investments, LLC with notifications on news.